NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are ...

Compare odds across 24 UK bookmakers for Fremad Amager vs HIK. Increase your potential winnings by using Oddschecker for a single bet or part of an acca.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The rejection came just a week ...

Vanda Pharmaceuticals (VNDA) lost ~11% in the premarket on Thursday after the U.S. FDA declined to approve a label expansion for its sleep disorder drug Hetlioz (tasimelteon) as a treatment for jet ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The cost of the approved drug ...

Vanda said the FDA approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic ...

The company filed a FDA application for its psoriasis drug Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 2.2% to trade at $7.06 at last check. The company announced last week it filed a ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...

Vanda Pharmaceuticals ((VNDA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Vanda and FDA's agreement includes expedited re-reviews of Tradipitant and Hetlioz applications, with target action dates in late 2025 and early 2026. The collaborative framework involves pausing ...

LONDON, 23 September 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the below listed Persons Discharging Managerial Responsibilities ("PDMRs") ...